71 |
Avaliação das margens cirúrgicas e do tipo de borda tumoral nas ressecções hepáticas por metástase de câncer colorretal e seu impacto na mortalidade e recidiva / Evaluation of surgical margins and the type of tumor growth pattern in colorectal liver metastases resection and its impact on mortality and recurrenceRafael Soares Nunes Pinheiro 24 May 2012 (has links)
INTRODUÇÃO: Aproximadamente 50% dos pacientes com tumor colorretal apresentam metástase hepática e a hepatectomia é o procedimento terapêutico de escolha. Discutem-se diversos fatores prognósticos, entre eles a margem cirúrgica é um fator sempre recorrente, pois não existe consenso da distância mínima necessária entre o nódulo metastático e a linha de secção hepática. Alguns autores identificaram que a margem cirúrgica maior que 1cm é um fator de melhor prognóstico com maior sobrevida e menor recidiva. Contudo, outros estudos demonstram resultados semelhantes entre pacientes com margens cirúrgicas maiores que 1cm, exíguas e até mesmo microscopicamente acometidas. Essas controvérsias conduzem à idéia de que outros fatores biológicos possam estar envolvidos na fisiopatologia de recorrência. Assim sendo, é de grande importância a avaliação da relação das margens cirúrgicas de ressecções hepáticas de metástases de câncer colorretal com a sobrevida e recidiva da doença. OBJETIVOS: Avaliar as margens cirúrgicas e o tipo de borda tumoral nas ressecções de metástases hepáticas de câncer colorretal e sua correlação com recidiva local e sobrevida. MÉTODOS: Estudo retrospectivo, baseado na revisão dos prontuários de 91 pacientes submetidos à ressecção de metástases hepáticas de neoplasia colorretal, durante o período compreendido entre janeiro de 2000 e dezembro de 2009. Revisão histopatológica prospectiva de todos os casos com aferição da menor margem cirúrgica e classificação das bordas tumorais como expansiva ou infiltrativa. RESULTADOS: Não houve diferença estatística nas taxas de recidiva e no tempo de sobrevivência global entre as margens livres e acometidas, assim como não houve diferença entre as margens subcentimétricas e maiores de 1cm. A sobrevida livre de doença dos pacientes com margens microscopicamente acometidas foi significativamente menor do que os pacientes com margens livres (p=0,002). A análise multivariada identificou o tipo de borda infiltrativa como fator de risco para recidiva (0,05). A sobrevida livre de doença foi significativamente menor nos pacientes com borda infiltrativa em comparação com os tumores com bordas expansivas (p=0,05). CONCLUSÕES: As ressecções de metástase hepática com margens livres de doença, independentemente da distância da margem, não influencia na recidiva tumoral (hepática ou extra-hepática) ou sobrevida do paciente. A borda tumoral do tipo infiltrativa foi fator de risco para recidiva / INTRODUCTION: Approximately 50% of patients with colorectal cancer have liver metastases and hepatectomy is the therapeutic procedure of choice. Surgical margin is an ever-recurring discussed prognostic factor, because there is no consensus of the minimum required distance between the metastatic nodule and the liver section line. Some authors reported surgical margin larger than 1 cm as a better prognosis factor ensuring longer survival rates and lower recurrence. However, other studies showed similar outcomes among patients with surgical margins larger than 1 cm, narrow margins and even microscopically affected ones. These controversies led the idea that other biological factors may be involved in the pathophysiology of recurrence. Therefore, it is valuable to assess the relationship between surgical margins of liver resection for colorectal cancer metastases with survival and recurrence. OBJECTIVES: To evaluate the surgical margins size and tumors growth pattern of colorectal liver metastases and its correlation with local recurrence and survival. METHODS: A retrospective study based on review of medical records of 91 patients undergoing resection of colorectal liver metastases during the period between January 2000 and December 2009. In addition, we undertook a detailed pathologic analysis of each pathological specimen with record of the closest surgical margins and tumors growth pattern classification as pushing or infiltrative. RESULTS: There was no statistical difference in recurrence rates and overall survival time between positive or negative margins, as well as no difference between the margins of 1cm width or more with subcentimeter margins. The disease-free survival of patients with microscopically positive margins was significantly lower than patients with negative margins (p = 0.002). Multivariate analysis identified infiltrative tumor growth pattern as a risk factor for recurrence (p=0.05). Disease-free survival was significantly lower in patients with infiltrative growth pattern compared to tumors with expansive margins (p = 0.05). CONCLUSIONS: Colorectal liver metastases resection with negative margins, regardless of width, has no influence on recurrence (hepatic or extrahepatic), neither on patient survival. The infiltrative tumor growth pattern type was a risk factor for recurrence
|
72 |
Identificação de microRNAs associados com recidiva em carcinoma papilífero da tireoide / Recurrence associated MicroRNAs in papillary thyroid cancerAdriana Sondermann de Afonseca 16 June 2015 (has links)
O carcinoma da glândula tireoide é o câncer endócrino mais prevalente, com crescente incidência anual. Dentre as neoplasias tireóideas, o carcinoma papilífero é o mais frequente, representando 80 a 90% destes tumores. A despeito do excelente prognóstico de seus portadores e da baixa taxa de mortalidade, cerca de 5% a 20% dos indivíduos submetidos à tireoidectomia total desenvolverão recidiva regional e todavia não há consenso sobre os fatores preditivos de recidiva tumoral. MicroRNAs são pequenos RNAs endógenos, que não codificam proteínas, e que medeiam a regulação póstranscricional da expressão gênica ligando-se seletivamente aos RNAs mensageiros por pareamento de bases. A expressão dos microRNAs de uma forma controlada exerce papel importante em múltiplos processos fisiológicos. Em contrapartida, em câncer, níveis de microRNAs podem estar diminuídos ou aumentados e existem evidências de que microRNAs estão envolvidos no processo de metástase e recidiva. No presente estudo, investigamos se os níveis de miR-9, miR-10b, miR-21 e miR-146b são preditores de recidiva em carcinoma papilífero de tireoide. Utilizando amostras de carcinoma papilífero de tireoide fixadas em formalina e emblocadas em parafina, avaliamos a expressão de miR-9, miR-10b, miR-21 e miR-146b em amostras de tumor primário de 66 pacientes através da PCR em tempo real. Os pacientes foram reunidos em dois grupos: pacientes que apresentaram recidiva tumoral (n=19) e pacientes que não apresentaram recidiva tumoral (n=47). Todos os pacientes foram submetidos à tireoidectomia total e seguidos por um tempo mínimo de 120 meses para serem considerados livres de recidiva. Comparamos os grupos de pacientes com e sem recidiva tumoral em relação às variáveis idade, sexo, tamanho do tumor, riscos ATA e MSKCC-NY, estadiamento TNM, variante histológica do tumor, presença de multicentricidade, invasão vascular e perineural, extensão extra-tireóidea e metástases linfonodais cervicais. Análises univariadas e multivariadas foram realizadas utilizando-se os modelos de riscos proporcionais de Cox. Conforme análise univariada, tamanho do tumor primário (p=0,001) e extensão extra-tireóidea (p=0,027) estão associados à recidiva tumoral. Da mesma forma, pacientes em estadios mais avançados (III e IV) segundo TNM (p=0,001) ou classificados em grupos de risco mais elevados segundo ATA (p=0,025) também apresentam maior risco de evoluírem com recidiva da doença. Observamos níveis de expressão de mir- 9 e miR-21 significativamente inferiores nos indivíduos que apresentaram recidiva quando comparados aos que não apresentaram recidiva neoplásica (p<0,001 e p=0,001, respectivamente). Os resultados deste estudo demonstraram que expressão diminuída de miR-9 ou de miR-21 é fator prognóstico significativo para recidiva em indivíduos portadores de carcinoma papilífero de tireoide quando avaliados em amostras do tumor primário (RR = 1,48; 95% IC: 1,24-1,77 e RR = 1,52; 95% IC: 1,18-1,94; respectivamente), enquanto miR-10b e miR-146 não se mostraram diferentemente expressos entre os dois grupos. A análises multivariada envolvendo os níveis de expressão de miR-9 e mR-21 e parâmetros clínicos indica que os níveis de expressão destes microRNAs são fatores prognósticos independentes para pacientes com carcinoma papilífero de tireoide. Concluindo, nossos resultados sugerem que o nível de expressão de miR-9 e miR-21 poderia ser utilizado na prática clínica como biomarcador para avaliar o potencial para recidiva em carcinoma papilífero de tireoide / Thyroid cancer is the most prevalent endocrine neoplasm, and its annual incidence continues to rise. Papillary thyroid cancer is the most common histological type, accounting for 80-90% of all thyroid cancers. Despite its excellent prognosis and low mortality rates, regional recurrence is observed in 5-20% of patients and there is still no consensus concerning tumor recurrence predictive factors. MicroRNAs are endogenous small noncoding RNAs that mediate, post-transcriptionally, gene expression regulation. MicroRNAs selectively bind to mRNAs, playing important roles in multiple physiological processes. On the other hand, microRNAs levels may be down regulated or over expressed in cancer, and have been implicated in recurrence and metastasis-related processes. In the present study, we investigated whether miR-9, miR-10b, miR-21 and miR-146b expression levels could be predictive factors of papillary thyroid cancer recurrence. Using macrodissection followed by quantitative real-time PCR, we measured miR-9, miR-10b, miR-21 and miR- 146b expression levels in formalin-fixed, paraffin-embedded primary tumor samples from 66 patients with papillary thyroid cancer. Patients were categorized into two groups: the recurrent group (n=19) and the non-recurrent group (n=47). All patients underwent total thyroidectomy and were followed for at least 120 months after surgery to be considered recurrence-free. Both groups were compared for clinical and pathological characteristics, including age, gender, tumor size, ATA and MSKCC-NY risk, TNM stage, multicentricity, vascular and perineural invasion, presence of cervical lymph node metastasis and histological type. Univariate and multivariate analysis were performed using the Cox proportional hazard analysis. Tumor size (p=0,001), extrathyroidal extension (p=0,027), higher risk ATA groups (p=0,025) and advanced TNM stages (p=0,001) were associated with recurrence. Expression levels of miR-9 and miR-21 were significantly lower in the recurrent group than in the nonrecurrent group (p<0,001 and p=0,001, respectively). MiR-9 and miR-21 expression levels were considered significant prognostic factors for recurrence in patients with papillary thyroid cancer (RR = 1,48; 95% CI: 1,24-1,77 and RR = 1,52; 95% CI: 1,18-1,94; respectively), but miR-10b and miR-146b were not. Multivariate analysis involving the expression levels of miR-9 and miR-21 and clinical parameters indicates that the expression levels are independent prognostic factor for papillary thyroid cancer patients. In conclusion, our results support the potential clinical value of miR-9 and miR-21 expression levels assessed in primary tumor samples as prognostic biomarkers for recurrence in papillary thyroid cancer
|
73 |
"Predição do risco de metástase do carcinoma bem diferenciado da glândula tireóide pela quantificação digital da imunoexpressão da galectina-3 nos compartimentos do tireócito maligno" / Prediction of metastasis risk in well-differentiated thyroid carcinoma based on digital quantification of galectin-3 immunoexpression in subcellular compartments of the malignant thyrocyteStabenow, Elaine 21 August 2006 (has links)
INTRODUÇÃO: Os carcinomas papilífero e folicular são neoplasias malignas primárias da glândula tireóide. Em conjunto, recebem o nome de carcinoma bem diferenciado. Determinar o risco individual da ocorrência de metástase nesses casos auxilia na seleção da terapêutica que é atualmente baseada na classificação de acordo com fatores prognósticos, aos quais pode ser associada a pesquisa de marcadores biológicos. Dentre eles, destaca-se a galectina-3, cujas funções exercidas nos compartimentos celulares foram descritas em uma variedade de neoplasias. Entretanto, seu papel no carcinoma tireóideo permanece controverso. Com o intuito de investigar se a galectina-3 pode auxiliar na predição do risco individual da ocorrência de metástase e se está associada aos critérios de malignidade do carcinoma bem diferenciado, a presente pesquisa objetivou verificar as seguintes hipóteses: 1) se há diferença da imunoexpressão da galectina-3 nos compartimentos do tireócito maligno entre os doentes com e sem metástase e se é possível predizer o risco de metástase em função da quantificação digital desse marcador; 2) se há diferença da imunoexpressão da galectina-3 entre o tecido tireóideo maligno e o não neoplásico; conforme a presença de invasão tecidual; e conforme a sobrevivência; 3) se há indício do envolvimento da galectina-3 com apoptose, indução da proliferação celular e angiogênese. MÉTODO: Trata-se de estudo retrospectivo de caso-controle que envolveu 109 doentes operados por carcinoma bem diferenciado da tireóide e seguidos por mais de cinco anos, distribuídos em dois grupos equivalentes: com e sem metástase. Foram feitos coleta de dados clínicos, avaliação anátomo-patológica e análise imunohistoquímica digital dos biomarcadores galectina-3, Ki-67, caspase-3 e CD-34. RESULTADOS: 1) A média do índice de positividade nucleolar da galectina-3 foi maior no grupo de doentes com metástase linfática cervical (1,78 ± 0,41 nucléolos/CGA contra 0,35 ± 0,13, p=0,004). A expressão nucleolar da galectina-3 apresentou especificidade de 75% para identificação da ocorrência de metástase e foi fator independente associado à ocorrência metástase linfática (p=0,01). A equação logística obtida permitiu calcular o risco individual de desenvolvimento de metástase linfática cervical que é próximo a 100% quando a galectina-3 está imunoexpressa em quatro ou mais nucléolos por campo microscópico de grande aumento. 2) não houve expressão da galectina-3 no tireócito não neoplásico; o índice de expressão citoplasmático foi fator independente associado à presença de invasão linfática (p=0,013) e a média desse índice foi maior nos casos com extensão extratireóidea (52,7 ± 3,9 uo/µm2 contra 41,0 ± 4,0, p=0,037); não houve associação dos índices de imunoexpressão da galectina-3 e sobrevivência; 3) no grupo de doentes com metástase, a expressão nucleoplasmática da galectina-3 correlacionou-se de forma positiva com o índice de positividade do Ki-67 e, nos dois grupos, a expressão citoplasmática com o índice de expressão da caspase-3. CONCLUSÕES: Foi possível predizer o risco individual da ocorrência de metástase linfática cervical em função da quantificação digital da imunoexpressão nucleolar da galectina-3. O presente estudo sugere que alta expressão citoplasmática está associada com algumas características de invasão local. Houve indícios do envolvimento da galectina-3 com indução da proliferação celular e apoptose no grupo de doentes com metástase. / INTRODUCTON: Papillary and follicular carcinomas are primary malignant neoplasias of the thyroid gland and are classified as well-differentiated carcinoma. In these cases, determination of individual risk of metastasis allows offering an adequate treatment. Nowadays therapy is chosen based on classification according to prognostic factors and biomarkers can be associated with them. Galectin-3 is one of these markers and has been thoroughly studied. A wide range of functions that it carries out in the subcellular compartments have been described in several neoplasms. However, its role in thyroid carcinomas remains controversial. In order to investigate if galectin-3 can be used to predict the individual risk of metastasis and if this marker is associated with malignant criteria of well-differentiated carcinoma, this study was proposed to verify the following hypotheses: 1) if galectin-3 immunostaining in subcellular compartments of the malignant thyrocyte is different when comparing patients with and without metastasis and if it is possible to predict the individual risk of metastasis based on digital quantification of the galectin-3 immunostaining; 2) if galectin-3 immunoexpression is different from malignant and benign thyroid tissue; according to tissue invasion and survival; 3) if there are indications that galectin-3 plays a role in apoptosis and cell proliferation or angiogenesis induction. METHODS: It was performed a retrospective case-control study involving 109 patients treated for well-differentiated thyroid carcinoma and followed up for more than five years. They were divided into two equivalent groups: with and without metastasis. The search of clinical data, morphological evaluation and digital immunohistochemical analysis with galectin-3, Ki-67, caspase-3 and CD-34 antibodies were done. RESULTS: 1) the average of the nucleolar galectin-3 positive index was higher in lymph node metastasis group (1.78 ± 0.41 nucleoli/HPF versus 0.35 ± 0.13, P=.004). Nucleolar staining was an independent factor associated with lymph node metastasis (P=.01) and its specificity to identify metastasis was 75%. The logistic model allowed predicting the individual risk of cervical lymph node metastasis. It was almost 100% for carcinomas displaying more than four galectin-3 immunostained nucleoli by microscopic high power field. 2) There was no galectin-3 immunostaining in non-neoplasic thyrocyte; the cytoplasmic galectin-3 expression index was an independent factor associated with lymphatic invasion (P=.013) and these index average was higher in cases with extrathyroidal extension (52.7 ± 3.9 uo/µm2 versus 41.0 ± 4.0, P=.037); there was no association of galectin-3 immunostaining indexes with survival; 3) in the metastasis group, there was positive correlation between nucleoplasmic staining of galectin-3 and Ki-67 positive index; there was positive correlation between cytoplasmic staining of galectin-3 and caspase-3 positive index in both groups. CONCLUSION: It was possible to predict the individual risk of cervical lymph node metastasis based on digital quantification of the nucleolar galectin-3 immunostaining. This study suggests that there is association of high cytoplasmic expression with local tissue invasion. In the metastasis group there were indications that galectin-3 plays a role in cell proliferation and apoptosis induction.
|
74 |
Ultrassonografia durante cirurgia para metástase cerebral: influência no índice de Karnofsky e volume do tumor residual / Ultrasonography during surgery to treat cerebral metastases: influence on Karnofsky index score and residual tumor volumeOliveira, Marcelo de Lima 30 May 2016 (has links)
Introdução: Os principais objetivos do tratamento das metástases cerebrais (MC) são no auxílio do controle da doença no encéfalo e a melhora da qualidade de vida dos pacientes. A cirurgia convencional tem um importante papel no tratamento das MCs e os métodos de monitoração intraoperatória podem auxiliar na obtenção de resultados cirúrgicos melhores. Objetivos: Avaliar a influência da ultrassonografia encefálica durante cirurgia para ressecção de MC no índice de Karnofsky e no grau de ressecção do tumor. Métodos: Neste estudo prospectivo controlado e não randomizado, doentes com indicação de tratamento cirúrgico de MCs foram incluídos. A ultrassonografia intraoperatória (USIO) foi realizada por um neurossonologista. O índice de Karnofsky foi avaliado por equipe multidisciplinar de oncologia; o grau de dificuldade para ressecção cirúrgica do tumor foi avaliado pelo cirurgião e o volume tumoral foi avaliado pelo neurorradiologista por meio da RM realizada no pré e pós-operatório. Resultados: Dos 78 doentes, 40 homens e 38 mulheres com idade média de 53 anos, 35 foram submetidos a tratamento cirúrgico com auxílio da USIO. Não houve diferença estatística no KPS e volume tumoral pré-operatório entre os grupos. O KPS pós-operatório no grupo da USIO foi de 80 e no grupo-controle de 70 (p=0,045). Considerando-se a melhora do KPS no pós-operatório, a quantidade de doentes tiveram melhora do KPS foi superior no grupo da USIO (p=0,036) destacando-se os seguintes subgrupos: tumores com grau de dificuldade de ressecção < 4 (p=0,037), tumores nas áreas eloquentes (p=0,043), tumores não relacionados aos grandes vasos e nervos (p=0,007), e lesões únicas no leito cirúrgico (p=0,038). O tumor residual na RM pós-operatória foi menor no grupo da USIO: 9,5% no grupo da USIO e 30,8% no grupo-controle; 1,6 mm3 no grupo da USIO e 9 mm3 do grupo-controle; p=0,05. Considerando-se doentes com KPS >= 70, o número de doentes com volume de tumor residual inferior a 10% em relação ao volume pré-operatório foi superior no grupo da USIO (p=0,032 e OR de 3,8). Conclusão: Os achados deste estudo sugerem que a USIO encefálica pode influenciar na melhora do índice de Karnofsky e na redução do volume de tumor residual / Object: The goals of treating a cerebral metastasis (CM) are to achieve local control of the disease and to improve patient quality of life. The aim of this study was to analyse the effect of using conventional surgery supported by intra-operative ultrasound (IOUS) to approach a CM. To perform this analysis, we determined Karnofsky post-operative scores (KPS) and tumour resection grades. Methods: Patients with CM who were eligible to undergo a surgical approach were included in this study. Surgical treatment was either supported or not supported by IOUS. A neural oncology team determined the pre- and post-operative KPS. A radiologist examined the tumour volume using pre- and post-operative magnetic resonance imaging. Before the surgery, the surgeon determined whether it was possible to perform a total CM resection. Results: A total of 78 patients with CM diagnosis were treated using a surgical approach (35 with and 43 without IOUS). The post-operative median KPS was higher in the IOUS group (80 versus 70, p=0.045). Within the IOUS group, KPS evolution was superior (p=0.036), especially in the following CM subgroups: a difficulty of tumour resection ranking score<4 (p=0.037), the tumour was in an eloquent area (p=0.043), the tumour was not associated with vessels or nerves (p=0.007), and solitary lesions (p=0.038). The volume of residual tumours was lower in the IOUS group (9.5% and 1.6 mm3 versus 30.8% and 9 mm3, p=0.05). In patients with a KPS >= 70, the residual tumour volume was categorized as < 10% or >= 10%, and 62% of patients had < 10% residual tumours (76% in the IOUS group and 45% in the non-IOUS group; p=0.032 and OR=3.8). Conclusion: This study suggests that IOUS can play a role in improving post-operative KPS and in decreasing residual tumours in CM surgeries
|
75 |
Clinical observation and experimental study of the efficacy of a Chinese medicine formula on maligant tumour bone metastasis diseases. / 中藥配方對惡性腫瘤骨轉移作用的臨床和實驗研究 / CUHK electronic theses & dissertations collection / Clinical observation and experimental study of the efficacy of a Chinese medicine formula on malignant tumour bone metastasis diseases. / Zhong yao pei fang dui e xing zhong liu gu zhuan yi zuo yong de lin chuang he shi yan yan jiuJanuary 2006 (has links)
At present, there is no cure for bone metastasis. The current goals in patient care are to palliate pain, prevent pathological bone fracture and increase the strength and function of bone, so as to extend the life expectancy and maintain a good quality of life. Bisphosphonate treatment is the currently standard therapy of bone metastasis and is commonly used by physicians; it alleviates the tumour-induced hypercalcemia in 90% of patients and reduces the metastatic bone pain in 50% of patients. Moreover, it also prevents the pathological fracture of the affected bones. However, while effective, bisphosphonate injections are very costly, though its oral formulation is less expensive it is also less efficacious, and causes gastrointestinal discomfort. Furthermore, prolonged use of bisphosphonate treatment may lead to certain adverse effects, including hypocalcemia. These factors will prohibit the longterm use of such medication as it can negatively affect the treatment outcome. / Based on enormous medical potentials illustrated by the aforementioned findings, BBYNG deserves wider clinical application, large-scale clinical study on its preventive effect against bone metastasis and detailed investigation of its mode(s) of action in the body. / Based on the above-described understanding of Chinese medicine and bone metastasis, supplementing the kidney and strengthening bone could be the basic principle for the treatment of bone metastasis using Chinese medicine. In view of this theory, and in addition to the clinical observation and a thorough search of the available literature, we selected relevant kidney-tonifying Chinese herbs, namely (Fructus Ligustri Lucidi), (Rhizoma Drynariae), (Herba Epimedii), (Psoralea Corylifolia) and wide-spectrum anticancer herbs (Herba Hedyotidis Diffusae) for the preparation of a combined formula--BBYNG. / Chinese medicine has long been used to treat cancers. Its advantages reside in its holistic properties, which bring palliative, corrective and convalescing functions against damage caused by radiotherapy, chemotherapy and surgery. These features position Chinese medicines as the adjuvant to orthodox cancer treatment. During the late stage of tumour development, when standard therapy is no longer effective, Chinese medicine plays a critical role as an integrated therapy. Searching for a safe, inexpensive and effective Chinese medicine preparation suitable for prolonged use as adjunct therapy in late cancer cases is of paramount importance. / Clinical results. Both Chinese medicine and Western medicine treated patients showed no significant change in their blood parameters or liver and kidney examinations before and after drug administration; Male subjects on BBYNG, their bone mass density remained stable after 6 months treatment and the subjects on OSTAC showed slightly decreased In females, subjects on BBYNG remained stable, but subjects on OSTAC slightly increased. / Clinical study. The study was designed as a randomized, parallel-group comparison between BBYNG formula and Bisphosphonate. The patients who meet the inclusion/exclusion criteria were randomly assigned to receive either BBYNG granules, which was prepared by a GMP manufacturer, or Clodronic acid. The treatment period was 6 months (24 weeks). For both groups, various clinical parameters such as body functions, blood examinations, bone density (BMD) assessment, X-ray examinations, pain intensity and quality of life were evaluated and compared. / Conclusions. (1) As an adjuvant to patients with bone metastases, BBYNG is effective in relieving the metastatic bone pain, improving the quality of life. (2) In the animal model, BBYNG reduced the metastatic bone damage, prolonged the survival and enhanced the T lymphocyte immunity in the tumour-bearing mice. (3) In vitro study on the breast and lung cancer cell lines showed that BYYNG could induce apoptosis and prevent tumour cell invasion. It suggests that BYYNG may restrict tumour growth and development, thus reducing the occurrence of bone metastasis. / In accordance with Chinese medicine, bone metastasis can be categorized into "bone tumour" "bone erosion" "bone wilting" "bone necrosis" and "bone impediment". The main cause of bone metastasis is twofold: cancer toxicity, and in Chinese medicine theory, the kidney governs the bone marrow, if the kidney is not functioning in balance, then the bone will become weak. Cancer toxicity is the "pathogenic cause" to skeletal metastases, while kidney weakness decreases the body defence against the cancer. A vicious cycle ensues when cancer and kidney deficiency and bone weakness occurs simultaneously coincidently and worsens the conditions. / In vitro study on tumour cell lines. The anticancer effects of different concentrations of BBYNG formula and various single components against human breast cancer and lung cancer cell lines were evaluated by cell viability test (MTT assay), cell apoptosis test and invasion suppression test. / In vitro study results. BBYNG and the aqueous extracts of its component herbs at very low drug concentrations stimulated the growth of three tumour cell lines tested. When the concentrations were slightly increased, they showed an inhibitory effect on cancer cell proliferation. As the drug concentrations further increased, the extracts showed cytotoxic effects on these tumor cells. At the noncytotoxic dose, the extracts could trigger apoptosis and enhance the caspase-3 activity in all three tumour cell lines. In addition, at this "non toxic" concentration, the extracts markedly inhibited the in vitro invasive property of the 4T1 breast cancer cell lines in our Matrigel invasion model. Thus these in vitro results suggested that BBYNG possess anticancer, invasion-inhibitory and anti-metastatic activities. / In vivo animal study results. (Tumour growth was slower in the BBYNG treatment group when compared to the OSTAC and control groups, but this was not significantly difference) BBYNG significantly delayed tumour growth in tumour bearing mice, but it did not minimize the tumour size markedly. Moreover, BBNYG did minimize the mobility restriction caused by tumours, reduce the damage to bones, prolong the survival time and enhanced the T lymphocyte immunity. / In vivo animal study. A well-established animal model for breast cancer was used to evaluate and compare the pharmacological effects of BBYNG formula and Clodronic acid, as shown by different indicators such as tumour progression, animal's mobility, survival time, bone metastasis-induced fracture intensity and the immunological status of the tumour-bearing mice. / Malignant tumour is characterized by early metastasis. Among them 37 to 80 (depending on which type of cancer) patients show tendency of bone metastasis. Bone metastasis is usually accompanied by various complications, such as severe pain, pathological bone fracture, hypercalcemia, and bone marrow suppression, which can substantially affect the quality of life of the patients. Thus, the prevention and treatment of bone metastasis in cancer is an issue worth pursuing. / Malignant tumours leading to high mortality and morbidity are a serious threat to human health. It is the leading cause of death in China. In Hong Kong, there are over 20 thousand new cancer cases and more than 1100 people die due to cancers every year. / Study objectives. To elucidate the efficacy and some pharmacological aspects of BBYNG in regard to the treatment of bone metastasis through clinical observation and different laboratory experiments. This study would be of significant reference value to the disease-oriented drug formulation and application, mechanistic study and research methodology of the treatment of bone metastasis using Chinese medicines. / The clinical and laboratory experimental results are summarized as below: / The research study is composed of three parts, the clinical study, in vivo animal study and in vitro study on tumour cell lines. The research methods used are as follows: / Those on BBYNG treatment showed more a stable and satisfactory quality of life than those in the Western medicine-treated group. For the Clodronic acid treatment group, patients generally showed worsened symptoms and quality of life deteriorated. The ECOG index of the BBYNG group was statistically better than that of the Clodronic acid group. Within the 72-week clinical observational period, the mortality of Clodronic acid group is significantly higher that of the BBYNG group. The effects of BBYNG group as presented in relieving the pain-induced influence on patients' emotion, interpersonal relationship and entertainment was more pronounced than that in the Clodronic acid group. / Wu Ka. / 論文(哲學博士)--香港中文大學, 2006. / 參考文獻(p. 299-324). / Adviser: Leung Ping Chung. / Source: Dissertation Abstracts International, Volume: 68-03, Section: B, page: 1570. / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Electronic reproduction. [Ann Arbor, MI] : ProQuest Information and Learning, [200-] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstracts in Chinese and English. / School code: 1307. / Lun wen (zhe xue bo shi)--Xianggang Zhong wen da xue, 2006. / Can kao wen xian (p. 299-324). / Wu Ka.
|
76 |
O uso de microRNA para tratamento do câncer de próstata: estudos in vitro e in vivo / The use of microRNA for the treatment of prostate cancer: in vitro and in vivo studiesIscaife, Alexandre 10 June 2016 (has links)
Introdução: O câncer de próstata (CaP) é o tumor mais comum do homem nos países ocidentais e a segunda causa de óbito por câncer em homens nos EUA, Europa e Brasil. O câncer localizado tem sobrevida câncer especifica elevada quando tratado adequadamente, porém a doença metastática ainda apresenta tratamentos pouco eficientes com sobrevida global de 28%. Os microRNAs (miRNAs) são um grupo de moléculas pequenas de RNA que contém entre 19 a 25 nucleotídeos não codificantes de proteína, com ação fundamental na regulação da expressão gênica. Eles estão envolvidos em processos essenciais nas células normais e neoplásicas como ciclo celular, proliferação, apoptose, metabolismo energético, invasão e metastatização. Objetivos: Realizar estudos in vitro e in vivo usando miRNA em um modelo de câncer de próstata metastático inédito no nosso meio com intuito de analisar o seu potencial como agente terapêutico dessa neoplasia. Métodos: Nos estudos in vitro, três linhagens celulares foram utilizadas (PC3, DU145 e LNCaP). Essas linhagens foram transfectadas com os miRNAs 100, 145 e 373 e seus respectivos antiMiRs utilizando-se lipofectamina. Analisamos a expressão dos genes alvo mTOR, SMARCA5, KRAS, CMYC, MMP9, CD44 por PCR quantitativo em tempo real (qRT-PCR). Foram realizados também estudos de apoptose, ciclo celular e ploidia utilizando o citômetro de fluxo. Alterações no potencial de invasão foram avaliadas pela técnica do matrigel. O modelo in vivo pré-clínico foi desenvolvido pela injeção intra-cardíaca da linhagem PC-3M-Luc-C6 em camundongos NUDE com 9 semanas. O crescimento tumoral foi avaliado com o sistema de bioluminescência in vivo. Após o pleno estabelecimento das metástases no dia 21, os animais foram tratados com três injeções na veia da cauda contendo o miRNA conjugado com o atelocolágeno. Os animais foram sacrificados e no dia 48 para análise dos tecidos. Resultados: miR-100 aumenta a apoptose na LNCaP, e reduz a apoptose na DU145. Na linhagem DU145 o miR 100 inibiu a proliferação. Na análise da expressão gênica o miR-100 inibe SMARCA5 na DU145 e PC3 e mTOR na LNCaP, o anti-miR 100 estimula mTOR e SMARCA5 na LNCaP. O miR-145 promoveu aumento da apoptose em 24% na DU145. Na linhagem PC3 o miR-145 age inibindo a proliferação, com uma diferença absoluta de 18% em relação ao seu controle. O miR-145 inibe KRAS e CMYC nas três linhagens e o anti-miR-145 estimula CMYC na DU145 e RAS nas três linhagens O miR-373 reduziu a apoptose em 29% na DU145 e diminui a proliferação com uma diferença absoluta de 13% em relação ao controle. O miR- 373 estimula a MMP9 na DU145 e na LNCaP e inibe o CD44 na PC3. O antimiR- 373 inibe MMP9 na DU145 e LNCaP. Nos estudos in vivo de CaP metastático o miR-100 apresenta tendência a redução no crescimento tumoral (p=0,23) e o miR-145 reduz o crescimento de forma significativa no dia 34 (p=0,02). Após esses dias o tumor volta a crescer de forma agressiva. Os animais tratados com anti-miR-373 não apresentaram alterações em relação aos controles. Conclusões: O miR-100 é um miRNA contexto dependente, com papel supressor tumoral em linhagens de tumor de próstata agressivo e o miR- 373 age in vitro como oncomiR. O miR-145 age como supressor tumoral in vitro e em modelo animal de CaP metastático apresentando resposta terapêutica consistente, podendo ser utilizado no arsenal terapêutico contra essa neoplasia. Estudos futuros devem avaliar o uso dos miRNAs isoladamente ou de forma adjuvante no tratamento do CaP metastático / Introduction: Prostate cancer (PCa) is the most common neoplasia of man in Western countries and the second cause of death by cancer in men in the US, Europe and Brazil. The localized cancer has high cancer-specific survival when treated properly, however metastatic disease still presents low effective treatments with 28% of global survival. microRNAs (miRNAs) are a group of small RNA molecules containing from 19 to 25 nucleotides of noncoding protein with fundamental action in the regulation of gene expression. They are involved in key processes in normal and neoplastic cells as cell cycle, proliferation, apoptosis, energy metabolism, invasion and metastasis. Objectives: To carry out studies in vitro and in vivo using miRNA in a novel model of metastatic prostate cancer in our country in order to evaluate its potential as a therapeutic agent of this neoplasia. Methods: In the in vitro studies, three cell lines were used (PC3, DU145 and LNCaP). These cell lines were transfected with miRNAs 100, 145 and 373 and their antiMiRs using lipofectamine. We analyzed the gene expression of mTOR, SMARCA5, KRAS, CMYC, MMP9, CD44 by real-time polymerase chain reaction (qRT-PCR). We also performed studies of apoptosis, cell cycle and ploidy using flow cytometer. Changes in the invasion potential were evaluated by the technique of matrigel. The pre-clinical model in vivo was developed by intracardiac injection of PC-3MLuc-C6 cell line in NUDE mice with 9 weeks. Tumor growth was evaluated with an in vivo image system (IVIS). After the full establishment of metastases on day 21, the animals were treated with three injections into the tail vein containing the miRNA plus atelocollagen. The animals were sacrificed on day 48 for tissues analysis. Results: MiR-100 increases apoptosis in LNCaP and reduces apoptosis in DU145. The anti-miR-100 increased apoptosis in 14% in PC3. In cell line DU145, miR-100 inhibited proliferation. In the analysis of gene expression, the miR-100 inhibits SMARCA5 in DU145 and PC3 and mTOR in LNCaP, anti-miR-100 stimulates mTOR and SMARCA5 in LNCaP. The miR-145 promoted an increased in apoptosis by 24% in DU145. In PC3 cell line miR-145 acts by inhibiting the proliferation, with an absolute difference of 18% compared to control. MiR-145 inhibits KRAS and CMYC in the three cell lines and anti-miR-145 stimulates CMYC in DU145 and KRAS in the three cell lines. The miR-373 reduced apoptosis by 29% in DU145 and reduces proliferation with an absolute difference of 13% relative to control. MiR-373 stimulates MMP9 in DU145 and LNCaP cells and inhibits CD44 in PC3. The anti -miR-373 inhibits MMP9 in DU145 and LNCaP. In the in vivo studies of metastatic PCa, miR-100 shows a tendency to decrease tumor growth (p=0.23) and miR-145 reduces tumor growth on day 34 (p=0.02). After those days, the tumor grows back aggressively. Animals treated with anti-miR-373 showed no changes relative to controls. Conclusion: The miR-100 is a context-dependent miRNA, with tumor suppressor role in aggressive tumor cell lines. The miR-373 acts in vitro as oncomiR and miR-145 acts as a tumor suppressor in vitro and in an animal model with consistent therapeutic response and can be used in the therapeutic arsenal against this neoplasia. Future studies should evaluate the use of miRNAs alone or adjuvant in the treatment of metastatic prostate cancer
|
77 |
A Src-Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth and metastasis in vitro and in vivo /Jallal, Houda. January 2007 (has links)
The central role of Src in the development of several malignancies including breast cancer and the accumulating evidence of its interaction with receptor tyrosine kinases (RTK), integrins and steroid receptors have identified it as an attractive therapeutic target. In the current study we have evaluated the effect of a Src/Abl kinase inhibitor SKI-606, on breast cancer growth, migration, invasion and metastasis. Treatment of human breast cancer cells MDA-MB-231 with SKI-606 caused a marked inhibition of cell proliferation, invasion and migration by inhibiting MAPK and Akt phosphorylation. For in vivo studies MDA-MB-231 cells transfected with the plasmid encoding green fluorescent protein (GFP) [MDA-MB-231-GFP] were inoculated into mammary fat pad of female BALB/c nu/nu mice. Once tumor volume reached 30-50 mm3, animals were randomized and treated with vehicle alone or 150 mg/kg of SKI-606 by daily oral gavage. Experimental animals receiving SKI-606 developed tumors of significantly smaller volume (45-54%) as compared to control animals receiving vehicle alone. Analysis of lungs, liver and spleen of these animals showed a significant decrease in GFP positive tumor metastasis in animals receiving SKI-606 at a dose that was well tolerated. Western blot analysis and immunohistochemical analysis of primary tumors showed that these effects were due to the ability of SKI-606 to block tumor cell proliferation, angiogenesis, growth factors expression and inhibition of Src mediated signalling pathways in vivo. Together the results from these studies provide compelling evidence for the use of Src inhibitors as therapeutic agents for blocking breast cancer growth and metastasis.
|
78 |
[Beta]₃ integrins enhance TGF-[beta]-mediated tumor progression in mammary epithelial cells /Galliher, Amy Jo. January 2007 (has links)
Thesis (Ph.D. in Pharmacology) -- University of Colorado Denver, 2007. / Typescript. Non-Latin script record Includes bibliographical references (leaves 112-128). Free to UCD affiliates. Online version available via ProQuest Digital Dissertations;
|
79 |
p63 and epithelial homeostasis studies of p63 under normal, hyper-proliferative and malignant conditions /Gu, Xiaolian, January 2010 (has links)
Diss. (sammanfattning) Umeå : Umeå universitet, 2010.
|
80 |
"Predição do risco de metástase do carcinoma bem diferenciado da glândula tireóide pela quantificação digital da imunoexpressão da galectina-3 nos compartimentos do tireócito maligno" / Prediction of metastasis risk in well-differentiated thyroid carcinoma based on digital quantification of galectin-3 immunoexpression in subcellular compartments of the malignant thyrocyteElaine Stabenow 21 August 2006 (has links)
INTRODUÇÃO: Os carcinomas papilífero e folicular são neoplasias malignas primárias da glândula tireóide. Em conjunto, recebem o nome de carcinoma bem diferenciado. Determinar o risco individual da ocorrência de metástase nesses casos auxilia na seleção da terapêutica que é atualmente baseada na classificação de acordo com fatores prognósticos, aos quais pode ser associada a pesquisa de marcadores biológicos. Dentre eles, destaca-se a galectina-3, cujas funções exercidas nos compartimentos celulares foram descritas em uma variedade de neoplasias. Entretanto, seu papel no carcinoma tireóideo permanece controverso. Com o intuito de investigar se a galectina-3 pode auxiliar na predição do risco individual da ocorrência de metástase e se está associada aos critérios de malignidade do carcinoma bem diferenciado, a presente pesquisa objetivou verificar as seguintes hipóteses: 1) se há diferença da imunoexpressão da galectina-3 nos compartimentos do tireócito maligno entre os doentes com e sem metástase e se é possível predizer o risco de metástase em função da quantificação digital desse marcador; 2) se há diferença da imunoexpressão da galectina-3 entre o tecido tireóideo maligno e o não neoplásico; conforme a presença de invasão tecidual; e conforme a sobrevivência; 3) se há indício do envolvimento da galectina-3 com apoptose, indução da proliferação celular e angiogênese. MÉTODO: Trata-se de estudo retrospectivo de caso-controle que envolveu 109 doentes operados por carcinoma bem diferenciado da tireóide e seguidos por mais de cinco anos, distribuídos em dois grupos equivalentes: com e sem metástase. Foram feitos coleta de dados clínicos, avaliação anátomo-patológica e análise imunohistoquímica digital dos biomarcadores galectina-3, Ki-67, caspase-3 e CD-34. RESULTADOS: 1) A média do índice de positividade nucleolar da galectina-3 foi maior no grupo de doentes com metástase linfática cervical (1,78 ± 0,41 nucléolos/CGA contra 0,35 ± 0,13, p=0,004). A expressão nucleolar da galectina-3 apresentou especificidade de 75% para identificação da ocorrência de metástase e foi fator independente associado à ocorrência metástase linfática (p=0,01). A equação logística obtida permitiu calcular o risco individual de desenvolvimento de metástase linfática cervical que é próximo a 100% quando a galectina-3 está imunoexpressa em quatro ou mais nucléolos por campo microscópico de grande aumento. 2) não houve expressão da galectina-3 no tireócito não neoplásico; o índice de expressão citoplasmático foi fator independente associado à presença de invasão linfática (p=0,013) e a média desse índice foi maior nos casos com extensão extratireóidea (52,7 ± 3,9 uo/µm2 contra 41,0 ± 4,0, p=0,037); não houve associação dos índices de imunoexpressão da galectina-3 e sobrevivência; 3) no grupo de doentes com metástase, a expressão nucleoplasmática da galectina-3 correlacionou-se de forma positiva com o índice de positividade do Ki-67 e, nos dois grupos, a expressão citoplasmática com o índice de expressão da caspase-3. CONCLUSÕES: Foi possível predizer o risco individual da ocorrência de metástase linfática cervical em função da quantificação digital da imunoexpressão nucleolar da galectina-3. O presente estudo sugere que alta expressão citoplasmática está associada com algumas características de invasão local. Houve indícios do envolvimento da galectina-3 com indução da proliferação celular e apoptose no grupo de doentes com metástase. / INTRODUCTON: Papillary and follicular carcinomas are primary malignant neoplasias of the thyroid gland and are classified as well-differentiated carcinoma. In these cases, determination of individual risk of metastasis allows offering an adequate treatment. Nowadays therapy is chosen based on classification according to prognostic factors and biomarkers can be associated with them. Galectin-3 is one of these markers and has been thoroughly studied. A wide range of functions that it carries out in the subcellular compartments have been described in several neoplasms. However, its role in thyroid carcinomas remains controversial. In order to investigate if galectin-3 can be used to predict the individual risk of metastasis and if this marker is associated with malignant criteria of well-differentiated carcinoma, this study was proposed to verify the following hypotheses: 1) if galectin-3 immunostaining in subcellular compartments of the malignant thyrocyte is different when comparing patients with and without metastasis and if it is possible to predict the individual risk of metastasis based on digital quantification of the galectin-3 immunostaining; 2) if galectin-3 immunoexpression is different from malignant and benign thyroid tissue; according to tissue invasion and survival; 3) if there are indications that galectin-3 plays a role in apoptosis and cell proliferation or angiogenesis induction. METHODS: It was performed a retrospective case-control study involving 109 patients treated for well-differentiated thyroid carcinoma and followed up for more than five years. They were divided into two equivalent groups: with and without metastasis. The search of clinical data, morphological evaluation and digital immunohistochemical analysis with galectin-3, Ki-67, caspase-3 and CD-34 antibodies were done. RESULTS: 1) the average of the nucleolar galectin-3 positive index was higher in lymph node metastasis group (1.78 ± 0.41 nucleoli/HPF versus 0.35 ± 0.13, P=.004). Nucleolar staining was an independent factor associated with lymph node metastasis (P=.01) and its specificity to identify metastasis was 75%. The logistic model allowed predicting the individual risk of cervical lymph node metastasis. It was almost 100% for carcinomas displaying more than four galectin-3 immunostained nucleoli by microscopic high power field. 2) There was no galectin-3 immunostaining in non-neoplasic thyrocyte; the cytoplasmic galectin-3 expression index was an independent factor associated with lymphatic invasion (P=.013) and these index average was higher in cases with extrathyroidal extension (52.7 ± 3.9 uo/µm2 versus 41.0 ± 4.0, P=.037); there was no association of galectin-3 immunostaining indexes with survival; 3) in the metastasis group, there was positive correlation between nucleoplasmic staining of galectin-3 and Ki-67 positive index; there was positive correlation between cytoplasmic staining of galectin-3 and caspase-3 positive index in both groups. CONCLUSION: It was possible to predict the individual risk of cervical lymph node metastasis based on digital quantification of the nucleolar galectin-3 immunostaining. This study suggests that there is association of high cytoplasmic expression with local tissue invasion. In the metastasis group there were indications that galectin-3 plays a role in cell proliferation and apoptosis induction.
|
Page generated in 0.0451 seconds